Global plasma protease C1-inhibitor treatment market is expected to grow at the highest CAGR in the upcoming years. C1-inhibitor is also known as C1-INH and C1 esterase inhibitor. C1-INH’s deficiency is the genetic defect underlying hereditary angioedema (HAE). Plasma protease C1-inhibitor concentrate is an effective and safe treatment for acute hereditary angioedema (HAE) attacks. The factors that play an important role in the growth of plasma protease C1-inhibitor treatment industry are prevalence of rare diseases, novel therapies, promising pipeline drugs, increasing investments in innovation of inhibitor drugs, and rising awareness regarding HAE.
Growth drivers for the plasma protease C1-inhibitor treatment market are rising practice of administering prophylactic treatment process for hereditary angioedema (HAE) patients, increasing demand for administering drugs internally among HAE patients, and new route for highly demand of C1-inhibitor drugs. This market is segmented on the basis of drug class, dosage type, distribution channel, and geography.
Based on drug class, the plasma protease C1-inhibitor treatment industry is classified as C1-inhibitors, kallikrein inhibitor (kalbitor), selective bradykinin B2 receptor antagonist (firazyr) and so on. The segment “C1-inhibitor” is sub-divided into C1-esterase inhibitor, recombinant inhibitor, and so on. Also, this segment held the highest market share in the past few years as C1-inhibitor drugs are usually used for the treatment of acute hereditary angioedema (HAE) and prophylaxis. Based on dosage type, the plasma protease C1-inhibitor treatment market is classified as liquid/injectable, lyophilized, and so on. The segment “lyophilized” held highest share in the past few years due to rising practice of intravenous administration of drugs for the treatment of HAE.
Based on distribution channel, the plasma protease C1-inhibitor treatment industry is classified as hospital pharmacies, independent pharmacies & outlets, and so on. Based on geography, the plasma protease C1-inhibitor treatment industry is classified as North America (U.S., Canada), Latin America (Brazil, Argentina, and Rest of Latin America), Europe (EU-5 Countries, BENELUX countries, Rest of Europe), and Rest of World (Israel, Australia, Rest of world countries).
Latin America and Asia Pacific are expected to control the lyophilized segment positively due to growth in high demand for intravenous C1 esterase inhibitor drugs market. Key players operating in the plasma protease C1-inhibitor treatment market are Shire plc, Sanquin, CSL Limited, Vertec Biosolvents, Somaiya Group, Pharming Group N.V., Yancheng Hongtai Bioengineering and Huade Biological Engineering.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Plasma Protease C1-inhibitor Treatment in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Plasma Protease C1-inhibitor Treatment market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Shire plc
• CSL Limited
• Pharming Group N.V.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
By Drug Class
• Kallikrein Inhibitor (Kalbitor)
• Selective Bradykinin B2 Receptor Antagonist (Firazyr)
By Dosage Type
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Hospital Pharmacies
• Independent Pharmacies and Outlets
Research Support Specialist, USA